Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Adam Kluska, Artur Chyrek, Wojciech Maria Burchardt, Marcin Włodarczyk, Grzegorz Bielęda, Adam Chicheł
{"title":"Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.","authors":"Adam Kluska, Artur Chyrek, Wojciech Maria Burchardt, Marcin Włodarczyk, Grzegorz Bielęda, Adam Chicheł","doi":"10.5603/rpor.103135","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.</p><p><strong>Materials and methods: </strong>We performed retrospective analysis of 39 IUR prostate cancer patients treated in our department with uLDR-BT between 2015-2019. All Patients had confirmed prostate cancer in biopsy and had local staging assessed with digital rectal examination and either transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) before treatment. Treatment was performed using <sup>125</sup>I seeds, and the dose prescribed to the clinical target volume was 145 Gy. After treatment, all patients were followed in our outpatient ambulatory one month after the procedure and every 3-6 months later on. Toxicity was assessed using the International Prostate Symptom Score (IPSS) and Radiation Therapy Oncology Group (RTOG) scales.</p><p><strong>Results: </strong>The median follow-up was 56,3 months [interquartile range (IQR): 36.9-73.4]. The mean nadir prostate-specific antigen (PSA) was 0.20 ng/mL (range 0.001-1.7). The actuarial 5-year biochemical failure-free survival (BFFS) was 87.02%. There was no statistically significant difference in BFFS between groups with antigen deprivation therapy (ADT) and without (p = 0.439). Analysis also showed no impact on BFFS of each intermediate group risk factors: initial PSA (iPSA) (p = 0.595). Gleason (p = 0.671) and Tumor stage (p = 0.694). There were no statistically significant differences in BFFS depending on number of those factors (p = 0.330).</p><p><strong>Conclusion: </strong>The uLDR-BT may be an effective option for selected IUR prostate cancer patients.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 5","pages":"600-605"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology and Radiotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/rpor.103135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.
Materials and methods: We performed retrospective analysis of 39 IUR prostate cancer patients treated in our department with uLDR-BT between 2015-2019. All Patients had confirmed prostate cancer in biopsy and had local staging assessed with digital rectal examination and either transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) before treatment. Treatment was performed using 125I seeds, and the dose prescribed to the clinical target volume was 145 Gy. After treatment, all patients were followed in our outpatient ambulatory one month after the procedure and every 3-6 months later on. Toxicity was assessed using the International Prostate Symptom Score (IPSS) and Radiation Therapy Oncology Group (RTOG) scales.
Results: The median follow-up was 56,3 months [interquartile range (IQR): 36.9-73.4]. The mean nadir prostate-specific antigen (PSA) was 0.20 ng/mL (range 0.001-1.7). The actuarial 5-year biochemical failure-free survival (BFFS) was 87.02%. There was no statistically significant difference in BFFS between groups with antigen deprivation therapy (ADT) and without (p = 0.439). Analysis also showed no impact on BFFS of each intermediate group risk factors: initial PSA (iPSA) (p = 0.595). Gleason (p = 0.671) and Tumor stage (p = 0.694). There were no statistically significant differences in BFFS depending on number of those factors (p = 0.330).
Conclusion: The uLDR-BT may be an effective option for selected IUR prostate cancer patients.
期刊介绍：
Reports of Practical Oncology and Radiotherapy is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. Reports of Practical Oncology and Radiotherapy is a journal of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists and the Greater Poland Cancer Centre, affiliated with the Spanish Society of Radiotherapy and Oncology, the Italian Association of Radiotherapy and the Portuguese Society of Radiotherapy - Oncology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
